Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pemetrexed plus bortezomib versus pemetrexed alone or bortezomib alone in previously treated advanced non-small cell lung cancer
2005-003357-27Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Dec 2005
- Modality
- Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing Alimta + VELCADE, Alimta alone and VELCADE alone (3 arms). Primary endpoint: Objective response rate. Started Dec 2005; status: completed.
02
Drugs
pemetrexedbortezomib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2005-003357-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-003357-27.